Breyanzi for the Treatment of Large B-cell Lymphoma, US
Breyanzi (lisocabtagene maraleucel) is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy indicated for the treatment of adult patients with …
Projects
-
-
FORZINITY (elamipretide) for Muscle Strength in Barth syndrome, USA
FORZINITY™ (elamipretide HCl) is indicated to enhance muscle strength in adult and paediatric patients with Barth syndrome who weigh at …
-
HERNEXEOS (zongertinib tablets) for the Treatment of HER-2 Mutant Advanced NSCLC, USA
HERNEXEOS® (zongertinib tablets) is a selective tyrosine kinase inhibitor (TKI) indicated for the treatment of adult patients with unresectable or …
-
ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2 positive advanced gastric cancer
Enhertu® (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate indicated for the treatment of various types of cancer, including gastric, breast, and …
-
PALSONIFY (paltusotine) for the Treatment of Acromegaly, USA
PALSONIFY™ (paltusotine) is a first-in-class, nonpeptide somatostatin receptor type 2 (SSTR2) agonist indicated as a first-line treatment for adults with …
-
COBENFY for the Treatment of Schizophrenia, US
COBENFY™ (xanomeline and trospium chloride) is an antipsychotic drug combining xanomeline, a muscarinic acetylcholine receptor (mAChR) agonist, and trospium chloride, …
-
BALVERSA for the Treatment of Urothelial Carcinoma, US
BALVERSA® (erdafitinib) is a fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of patients with locally advanced or …
-
Iqirvo for the Treatment of Primary Biliary Cholangitis, US
Iqirvo® (elafibranor) is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in …
-
Sarclisa (isatuximab) for the Treatment of Multiple Myeloma, USA
Sarclisa® (isatuximab) is a monoclonal antibody indicated, in combination with pomalidomide and dexamethasone (pom-dex), for the treatment of multiple myeloma …
-
FRUZAQLA (fruquintinib) for the Treatment of Metastatic Colorectal Cancer, USA
FRUZAQLA® (fruquintinib) is a kinase inhibitor indicated to treat adults with metastatic colorectal cancer (mCRC). It is a novel oral targeted …
-
VYLOY (zolbetuximab) for the Treatment of Gastric Cancer, Japan
VYLOY™ (zolbetuximab) is an anti-claudin (CLDN)-18.2 monoclonal antibody used in conjunction with chemotherapy for the treatment of patients with human …
-
NIKTIMVO for the Treatment of cGvHD, US
NIKTIMVO™ (axatilimab) is a first-in-class anti-colony stimulating factor-1 receptor (CSF-1R) antibody indicated for treating the chronic graft-versus-host disease (cGvHD) in …
-
Wegovy for the Treatment of Chronic Weight Management, US
Wegovy® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced diet and increased exercise …
-
Livdelzi (Seladelpar) for the Treatment of Primary Biliary Cholangitis, USA
Livdelzi® (seladelpar) is a novel, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. It is indicated for the treatment of primary …
-
TECELRA (afamitresgene autoleucel) for the Treatment of Synovial Sarcoma, USA
TECELRA® (afamitresgene autoleucel) is an autologous T-cell immunotherapy indicated for adults with unresectable or metastatic synovial sarcoma who test positive …
